Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Generalized prurigo nodularis with dramatic response to dupilumab treatment: A case report
Cagdas Boyvadoglu, Huseyin Serhat Inaloz, Department of Dermatology, University of Gaziantep Faculty of Medicine, Gaziantep 27270, Turkey
Author contributions: Boyvadoglu C and Inaloz HS contributed equally to this work; Boyvadoglu C and Inaloz HS designed the report; Boyvadoglu C wrote the manuscript; All authors have read and approve the final manuscript.
Informed consent statement: Written informed consent to publish this case (including images) was obtained from the patient.
Conflict-of-interest statement: The authors declare no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huseyin Serhat Inaloz, Doctor, Professor, Department of Dermatology, University of Gaziantep Faculty of Medicine, Gaziantep Üniversitesi Şahinbey Araştırma ve Uygulama Hastanesi Üniversite Bulvar P.K. 27310, Şehitkamil / Gaziantep, Gaziantep 27270, Turkey. serhatinaloz@hotmail.com
Received: October 14, 2022
Peer-review started: October 14, 2022
First decision: November 4, 2022
Revised: November 10, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 16, 2023
Processing time: 93 Days and 16 Hours
Peer-review started: October 14, 2022
First decision: November 4, 2022
Revised: November 10, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 16, 2023
Processing time: 93 Days and 16 Hours
Core Tip
Core Tip: Prurigo nodularis (PN) is a difficult disease to treat and causes frustration to both the patient and the treating doctor. Treatment of PN is based on clinical experience rather than controlled trials. PN is a disease that negatively affects the quality of life of patients due to severe itching. Patients often receive limited benefit from first-line treatments and require systemic therapy. Dupilumab treatment stands out as an effective and safe systemic treatment agent among existing systemic treatments. In this case, we show how effective and well tolerated treatment with dupilumab is in the treatment of recalcitrant PN.